Professor | 贺金雪 | 数字化转型顾问

Name	贺金雪
Contact Information	jinxue_he@simm.ac.cn
Language ability	中文, 英语
Province	上海

Name

贺金雪

Contact Information

jinxue_he@simm.ac.cn

Language ability

中文, 英语

Province

上海

University/Lab Affiliation and Title	中国科学院大学
Faculty	Medical School
Academic Background & Achievements	2007-09--2012-07 博士: 中国科学院上海药物研究所 2003-09--2007-07 本科: 山东大学
Work Experience	2019-10~现在 - 中国科学院上海药物研究所 - 研究员 2016-10~2019-09 - 中国科学院上海药物研究所 - 副研究员 2016-02~2016-09 - 中国科学院上海药物研究所 - 助理研究员 2012-09~2016-01 - Weill Cornell Medicine - 博士后

University/Lab Affiliation and Title

中国科学院大学

Faculty

Medical School

Academic Background & Achievements

2007-09--2012-07 博士: 中国科学院上海药物研究所
2003-09--2007-07 本科: 山东大学

Work Experience

2019-10~现在 - 中国科学院上海药物研究所 - 研究员
2016-10~2019-09 - 中国科学院上海药物研究所 - 副研究员
2016-02~2016-09 - 中国科学院上海药物研究所 - 助理研究员
2012-09~2016-01 - Weill Cornell Medicine - 博士后

Areas of Focus	抗肿瘤新药研发和作用机制研究 DNA损伤修复通路及核内蛋白的干预研究靶向泛素蛋白酶体途径的新药研发
Publications	Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy, 贺金雪, 2024 YCH1899, a Highly Effective Phthalazin-1(2 H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors, 贺金雪, 2023 Identification of 1,2,4Triazolo4,3-apyrazine PARP1 inhibitors with overcome acquired resistance activities, 贺金雪, 2023 Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance, 贺金雪, 2023 SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy, 贺金雪, 2022 Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone, 贺金雪, 2022 Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold, 贺金雪, 2021 Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers, 贺金雪, 2021 Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer, 贺金雪, 2021 Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors, 贺金雪, 2020 Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity, 贺金雪, 2019 Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression, 贺金雪, 2018 Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors, 贺金雪, 2017 Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution, 贺金雪, 2017 Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials, 贺金雪, 2017 PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis, 贺金雪, 2016 PTEN Regulates DNA Replication Progression and Stalled Fork Recovery, 贺金雪, 2015

Areas of Focus

抗肿瘤新药研发和作用机制研究
DNA损伤修复通路及核内蛋白的干预研究
靶向泛素蛋白酶体途径的新药研发

Publications

Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy, 贺金雪, 2024
YCH1899, a Highly Effective Phthalazin-1(2 H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors, 贺金雪, 2023
Identification of 1,2,4Triazolo4,3-apyrazine PARP1 inhibitors with overcome acquired resistance activities, 贺金雪, 2023
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance, 贺金雪, 2023
SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy, 贺金雪, 2022
Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone, 贺金雪, 2022
Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold, 贺金雪, 2021
Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers, 贺金雪, 2021
Glycogen synthase kinase 3 beta inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer, 贺金雪, 2021
Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors, 贺金雪, 2020
Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity, 贺金雪, 2019
Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression, 贺金雪, 2018
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors, 贺金雪, 2017
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution, 贺金雪, 2017
Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials, 贺金雪, 2017
PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis, 贺金雪, 2016
PTEN Regulates DNA Replication Progression and Stalled Fork Recovery, 贺金雪, 2015

抗肿瘤药物研发机制研究 Dna损伤修复通路核内蛋白干预泛素蛋白酶体新药

郭彬 - 中国科学院大学

Area of Focus
抗感染 | 抗肿瘤 | 抗血栓 | 药物研发 | 小分子 | 创新药物 | 研究 | 药品 | 药物化学 | 临床研究

胡成俊 - 武汉大学

Area of Focus
心血管 | 生物学 | 间充质 | 基质 | 细胞 | 自噬 | 衰老 | 泛素 | 蛋白酶体 | 缺血

View All

Personal Information

Academic Information

Research

联系我们

还未创建账户?

Personal Information

Academic Information

Research

联系我们